Latest Health News

Page 9 of 271
Mayne Pharma’s unaudited first-quarter revenue fell 2% to A$95.7 million, while underlying EBITDA dropped 52% as generic competition hit Dermatology. Strong prescription growth in Women’s Health and DistributeRx offered a partial counterweight, alongside progress on key legal disputes.
Victor Sage
Victor Sage
26 Oct 2026
Artrya has converted its largest US customer and first SAPPHIRE Study participant into a five-year commercial agreement, while delaying its planned Coronary Flow FDA submission to strengthen clinical evidence. The Salix rollout is gaining traction, but revenue remains early and scan volumes are undisclosed.
Victor Sage
Victor Sage
26 Oct 2026
Cochlear has reaffirmed FY27 underlying net profit guidance of $330 million to $350 million after a disappointing FY26, while pointing to strong Nexa adoption and progress on fully implantable hearing technology. The company is cutting fixed costs and expanding medical referral pathways as it seeks to convert a large pool of untreated adult hearing loss into growth.
Victor Sage
Victor Sage
26 Oct 2026
Echo IQ’s FDA-cleared EchoSolv AS platform processed 9,697 full-result assessments in the September quarter, while the company ended the period with A$107.8 million in cash. The stronger balance sheet gives it room to pursue US enterprise deployments, but commercial conversion and the unresolved EchoSolv HF regulatory pathway remain the key tests.
Victor Sage
Victor Sage
26 Oct 2026
Structural Monitoring Systems remained profitable in the September quarter, but revenue, earnings and free cash flow all fell as aircraft maintenance delays weighed on avionics sales. The company also said Boeing’s FAA approval pathway for its 737NG structural monitoring application is taking longer than expected, with no revised completion date.
Victor Sage
Victor Sage
26 Oct 2026
Beamtree Holdings has paired 10% recurring revenue growth with a $13.1 million non-cash impairment and a year-end debt covenant breach. The ASX-listed healthcare software company is betting that a tighter product portfolio, new leadership and FY27 execution can stabilise the balance sheet.
Victor Sage
Victor Sage
23 Oct 2026
PeopleIN improved underlying earnings and reduced leverage in FY26 despite a statutory loss, as Queensland’s infrastructure demand drove a sharp recovery in its core workforce division. The company is now betting that a leaner portfolio, Infrawork’s trans-Tasman labour channel and Brisbane 2032-related work can sustain the upturn.
Victor Sage
Victor Sage
23 Oct 2026
Monash IVF Group’s underlying NPAT fell 41% to A$16.1 million in FY26, missing its recently reduced guidance as softer Australian IVF activity outweighed international growth. A second-half market-share recovery, lower planned capital spending and a new productivity program now carry the FY27 investment case.
Ada Torres
Ada Torres
23 Oct 2026
Firebrick Pharma is escalating Nasodine’s US push from online sales into retail pharmacies while its September-quarter cash balance fell to A$875,000. The company reported a A$398,000 operating cash outflow and estimated 2.2 quarters of funding at the current rate.
Victor Sage
Victor Sage
23 Oct 2026
Argent BioPharma ended the September quarter with just A$11,000 in cash after A$734,000 of operating outflows, despite retaining A$7.4 million of unused convertible financing capacity. The company is simultaneously expanding its commercial portfolio through NLC antiviral rights and a CannEpil veterinary programme.
Victor Sage
Victor Sage
23 Oct 2026
Racura Oncology says both Phase 1 RC220 programs have cleared their opening dose cohorts without dose-limiting toxicities, while its Korean expansion broadens the CPACS trial. The company ended September with $30.7 million in cash, which management says funds committed activities into mid-2028.
Victor Sage
Victor Sage
22 Oct 2026
Cleanaway has reaffirmed FY27 underlying EBIT guidance of $500 million to $530 million as its proposed EQT Infrastructure takeover moves into the approval process. The AGM also disclosed a second strike against the remuneration report, alongside sharply reduced executive incentive outcomes and continued scrutiny of safety and cash conversion.
Victor Sage
Victor Sage
22 Oct 2026

Browse the archive

Full archive